Folgen
Ron van Schaik
Ron van Schaik
Professor Pharmacogenetics, Erasmus
Bestätigte E-Mail-Adresse bei erasmusmc.nl
Titel
Zitiert von
Zitiert von
Jahr
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
FH Schröder, J Hugosson, MJ Roobol, TLJ Tammela, M Zappa, V Nelen, ...
The Lancet 384 (9959), 2027-2035, 2014
10912014
Pharmacogenetics: from bench to byte—an update of guidelines
JJ Swen, M Nijenhuis, A de Boer, L Grandia, AH Maitland‐van der Zee, ...
Clinical Pharmacology & Therapeutics 89 (5), 662-673, 2011
10472011
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
DA Hesselink, RHN van Schaik, IP Van Der Heiden, M van der Werf, ...
Clinical Pharmacology & Therapeutics 74 (3), 245-254, 2003
8162003
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up
FH Schroder, J Hugosson, MJ Roobol, TLJ Tammela, M Zappa, V Nelen, ...
Lancet 384 (9959), 2027-2035, 2014
6852014
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ...
Nature genetics 50 (7), 928-936, 2018
5962018
A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to …
WJ Catalona, AW Partin, MG Sanda, JT Wei, GG Klee, CH Bangma, ...
The Journal of urology 185 (5), 1650-1655, 2011
5472011
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing
KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ...
Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015
5032015
CYP3A5 Variant Allele Frequencies in Dutch Caucasians
RHN van Schaik, IP van der Heiden, JN van den Anker, J Lindemans
Clinical chemistry 48 (10), 1668-1671, 2002
3882002
Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report
M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ...
Therapeutic drug monitoring 41 (3), 261-307, 2019
3292019
Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection
FH Jansen, RHN van Schaik, J Kurstjens, W Horninger, H Klocker, ...
European urology 57 (6), 921-927, 2010
3122010
Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study
ML Becker, LE Visser, RHN van Schaik, A Hofman, AG Uitterlinden, ...
Diabetes 58 (3), 745-749, 2009
2982009
Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism
D Burger, I Van Der Heiden, C La Porte, M Van Der Ende, P Groeneveld, ...
British journal of clinical pharmacology 61 (2), 148-154, 2006
2822006
The prostate health index selectively identifies clinically significant prostate cancer
S Loeb, MG Sanda, DL Broyles, SS Shin, CH Bangma, JT Wei, AW Partin, ...
The Journal of urology 193 (4), 1163-1169, 2015
2712015
A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients
L Elens, R Bouamar, DA Hesselink, V Haufroid, IP van der Heiden, ...
Clinical chemistry 57 (11), 1574-1583, 2011
2662011
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus
ML Becker, LE Visser, RHN Van Schaik, A Hofman, AG Uitterlinden, ...
The pharmacogenomics journal 9 (4), 242-247, 2009
2482009
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation
DA Hesselink, R Bouamar, L Elens, RHN Van Schaik, T Van Gelder
Clinical pharmacokinetics 53, 123-139, 2014
2452014
DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis
LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ...
The Lancet Oncology 19 (11), 1459-1467, 2018
2312018
The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients
M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ...
European urology 71 (4), 680-687, 2017
2282017
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
MP Goetz, K Sangkuhl, HJ Guchelaar, M Schwab, M Province, ...
Clinical Pharmacology & Therapeutics 103 (5), 770-777, 2018
2272018
Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics
FM de Man, AKL Goey, RHN van Schaik, RHJ Mathijssen, S Bins
Clinical pharmacokinetics 57, 1229-1254, 2018
2252018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20